
Peking University First Hospital has a total capacity of 1,805 beds across three campuses: Central, Miyun, and Daxing. The hospital delivers a full range of inpatient and outpatient services, serving patients across China and internationally.
Established in 1915, Peking University First Hospital (PUFH) is one of China's most prestigious medical institutions, affiliated with the Peking University Health Science Center. As a top-tier tertiary hospital classified as Grade 3A, it is recognized for its leadership in clinical excellence, education, and research. Over the decades, PUFH has been pioneering in shaping modern Chinese medicine, particularly in specialties such as urology, nephrology, pediatrics, neurology, cardiology, and organ transplantation.
The hospital is home to a team of highly qualified doctors and professors, including many national-level experts. Known for managing complex and rare diseases, it continues to advance patient care through innovation, multidisciplinary collaboration, and compassionate treatment.
Advanced Technology & Facilities
Key Services at Peking University First Hospital
Peking University First Hospital blends a century of medical heritage with high-quality clinical care, innovative research, and comprehensive education. It stands as a benchmark of excellence in China, committed to improving patient outcomes through multidisciplinary collaboration and compassionate, personalized care.

The hospital has approximately 50 inpatient beds in its main campus, along with nine satellite clinics across Beijing. It manages over 2,500 outpatient visits each week and provides care to hundreds of thousands of patients annually, both local and international.
Beijing United Family Hospital (BJU) is one of China’s most prestigious private medical institutions, known for delivering world-class healthcare that meets international standards. Established in 1997, it was the first foreign-invested hospital in China and has since become a trusted choice for both International and Chinese patients seeking high-quality, patient-focused care. As part of the United Family Healthcare network, BJU has built a reputation for medical excellence, advanced technology, and a uniquely personalized approach to treatment.
The hospital is staffed by a diverse team of internationally trained doctors, many of whom have practiced in top healthcare systems across the U.S., Europe, and Asia. This global expertise is complemented by the latest medical equipment, multilingual support services, and a strong commitment to clinical safety and patient satisfaction. Recognized by the Joint Commission International (JCI) for meeting the highest standards in healthcare delivery, BJU offers a full spectrum of medical services across numerous specialties, including family medicine, internal medicine, orthopedics, oncology, cardiology, obstetrics, pediatrics, and plastic surgery.
Advanced Technology & Facilities
Key Services at BJU
Beijing United Family Hospital stands as a pioneer in international-standard healthcare in China, blending modern technology, world-class medical expertise, and a warm, comprehensive approach to family health.

As part of Singapore‑listed Raffles Medical Group, founded in 1976, RMG China operates 5 tertiary hospitals and over 100 clinics, supported by 430+ physicians and 900+ nurses & allied health professionals, delivering comprehensive inpatient and outpatient services.
Raffles Medical Group has operated in China since 2010, growing into a trusted name among both local and expatriate communities. All RMG China hospitals and clinics follow the Group’s Institutional Group Practice Model, which emphasizes integrated, peer-reviewed, and clinically audited care. Backed by Raffles Hospital Singapore, accredited by Joint Commission International (JCI), the network ensures alignment with global standards for quality and patient safety. With a rigorous clinical governance framework, strategic insurance and corporate partnerships, and a presence in key Chinese cities, RMG serves over 2.8 million patients annually. The Group continues to expand across China, offering world-class healthcare that combines international expertise with localized, patient-centered care.
Advanced Technology & Facilities
Key Services at Raffles Medical Group China
Raffles Medical Group China is a leading integrated private hospital network, delivering high-quality, multidisciplinary medical care in major Chinese cities. With its robust institutional infrastructure, advanced diagnostic and treatment facilities, and a reputation anchored by the Singapore-based Raffles Hospital, RMG China continues to expand and uphold global healthcare standards.



Fertility care in China is delivered within a centrally regulated healthcare system overseen by the National Health Commission, where reproductive medicine and assisted reproductive technologies (ART) are subject to some of the country’s most detailed medical regulations. In recent years, fertility services have continued to modernize in response to demographic changes and national public health priorities. Many accredited hospitals now integrate advanced laboratory systems, digital diagnostics, embryo monitoring technologies, and standardized electronic medical records to support accuracy, traceability, and patient safety across fertility services.
Physicians working in fertility and reproductive medicine in China follow clearly defined education, certification, and licensing pathways. After completing a medical degree and national licensing examinations, doctors undergo structured postgraduate training in obstetrics and gynecology or urology, followed by subspecialty training in reproductive medicine. Authorization to perform assisted reproductive technologies, such as in vitro fertilization (IVF), is granted only to hospitals and clinicians who meet strict regulatory criteria, including laboratory standards, staff qualifications, and ongoing quality audits. Many fertility specialists also hold academic positions in university-affiliated hospitals, contributing to research, teaching, and the continuous refinement of clinical protocols.
Hospital infrastructure supporting fertility treatment in China is largely concentrated in tertiary-care and university-affiliated medical centers. These institutions house specialized reproductive medicine departments, embryology laboratories with controlled environments, advanced imaging and diagnostic units, and multidisciplinary teams that include endocrinologists, embryologists, anesthesiologists, and genetic counselors. Academic affiliation supports clinical governance, ethical oversight, and adherence to evidence-based medicine, reinforcing consistency and accountability in fertility care.
For foreign patients, several practical considerations are commonly addressed early in the planning process. Most international visitors require a valid visa to enter China, sometimes supported by a hospital-issued invitation letter confirming medical consultation. Fertility treatments often involve multiple visits rather than a single hospital stay, and patients may need to plan for stays ranging from several days to a few weeks depending on diagnostic and treatment phases. Language barriers can arise, although many large hospitals operate international patient departments that arrange English-speaking staff or professional medical interpreters. Follow-up care planning after returning home is an important aspect of fertility treatment coordination, and hospitals typically provide detailed test results, treatment summaries, and laboratory documentation to support continuity with local healthcare providers.
In practice, patients typically begin exploring fertility treatment options by reviewing hospital accreditation status or contacting international patient offices for general information. Hospitals often request prior medical records such as hormone test results, ultrasound reports, semen analysis, and previous fertility treatment documentation for preliminary review. Communication commonly takes place via email or secure online platforms, where administrative teams clarify documentation requirements, consent procedures, laboratory timelines, and non-clinical logistics. Patients and families frequently ask about regulatory eligibility, testing schedules, appointment coordination, and documentation needs rather than specific treatment recommendations or outcomes.
Modern fertility care in China reflects the structured integration of advanced reproductive technologies with comprehensive patient safety and regulatory oversight. Many accredited centers utilize digital diagnostics, automated hormone analysis, high-resolution ultrasound, and time-lapse embryo monitoring systems to support precise assessment and laboratory quality control. Embryology laboratories are subject to strict environmental standards, equipment validation, and continuous monitoring to ensure diagnostic accuracy and procedural safety.
Institutional protocols emphasize infection control, specimen identification, imaging safety, anesthesia oversight for procedural interventions, and post-procedure monitoring. Fertility treatments are delivered through standardized care pathways that include informed consent, ethical review, and detailed documentation. Multidisciplinary teams collaborate to ensure laboratory accuracy, patient safety, and regulatory compliance throughout each stage of care.
Continuous professional development is mandatory for fertility specialists and embryologists in China. Clinicians regularly participate in continuing medical education, national and international conferences, and skills-based laboratory training. Treatment plans are individualized, informed consent is required, and final clinical decisions depend on professional evaluation by licensed specialists within authorized institutions. At a national level, China is widely recognized for maintaining stringent regulatory control and structured oversight of assisted reproductive technologies.
In vitro fertilization involves fertilizing an egg with sperm in a controlled laboratory environment before embryo transfer. Diagnostic planning typically includes hormonal evaluation, ultrasound imaging, and laboratory testing. Safety protocols emphasize specimen identification, laboratory sterility, and clinical oversight throughout stimulation, retrieval, and transfer phases.
ICSI is a laboratory technique used to assist fertilization by injecting a single sperm into an egg. The procedure is performed by trained embryologists using micromanipulation equipment under strict quality control standards. Oversight focuses on laboratory safety, accurate documentation, and embryo handling protocols.
Ovulation induction involves stimulating the ovaries to promote egg development. Monitoring typically includes ultrasound imaging and hormone testing to assess response. Safety protocols emphasize individualized planning, diagnostic accuracy, and clinical supervision throughout treatment cycles.
Fertility preservation includes cryopreservation of eggs, sperm, or embryos for future use. Procedures rely on controlled freezing technologies, secure storage systems, and detailed record-keeping. Clinical oversight focuses on specimen integrity, consent documentation, and long-term laboratory safety.
PGT involves genetic analysis of embryos prior to transfer. Diagnostic planning includes laboratory biopsy techniques and genetic screening under regulated conditions. Safety and ethical oversight are emphasized, with strict adherence to national guidelines governing genetic testing.
Reproductive endocrinology consultations focus on evaluating hormonal and reproductive health factors. Diagnostic methods include laboratory testing and imaging, with care delivered under standardized clinical governance and documentation frameworks.
Peking University Third Hospital
Accreditations: National Health Commission oversight; Peking University affiliation.
Specializations: Known for reproductive medicine and assisted reproductive technologies within a large academic and research-focused environment.
Peking Union Medical College Hospital
Accreditations: National Health Commission oversight; Peking Union Medical College affiliation.
Specializations: Provides fertility and reproductive endocrinology services supported by multidisciplinary academic teams and advanced diagnostics.
Shanghai Ninth People’s Hospital
Accreditations: National Health Commission oversight; Shanghai Jiao Tong University School of Medicine.
Specializations: Offers assisted reproductive technologies within a high-volume academic hospital emphasizing laboratory quality and clinical governance.
West China Second University Hospital
Accreditations: National Health Commission oversight; Sichuan University affiliation.
Specializations: Focuses on reproductive medicine, obstetrics, and gynecology with integrated research and teaching programs.
Ruijin Hospital
Accreditations: National Health Commission oversight; Shanghai Jiao Tong University School of Medicine.
Specializations: Provides fertility and reproductive endocrinology services within a tertiary academic hospital setting.
Zhongshan Hospital Fudan University
Accreditations: National Health Commission oversight; Fudan University affiliation.
Specializations: Integrates reproductive medicine services with endocrinology and laboratory diagnostics in a multidisciplinary environment.
Guangzhou Women and Children’s Medical Center
Accreditations: National Health Commission oversight; university teaching affiliation.
Specializations: Provides assisted reproductive technologies and fertility services within a specialized maternal and child health framework.
| Fertility Procedure | Estimated Cost Range (USD) |
| IVF Cycle | $4,000-$8,000 |
| ICSI Procedure | $1,500-$3,500 |
| Ovulation Induction & Monitoring | $800-$2,000 |
| Fertility Preservation (Cryopreservation) | $1,000-$4,000 |
| Preimplantation Genetic Testing (PGT) | $2,500-$6,000 |
| Fertility Diagnostic Workup | $500-$1,500 |
Note: The prices listed above are approximate, non-binding estimates provided for general informational purposes only. Actual treatment costs may vary based on individual clinical requirements, diagnostic findings, treatment complexity, materials or technology used, physician expertise, facility type, and duration of care. Final pricing is determined only after a professional evaluation by a licensed specialist or accredited medical institution.
Fertility treatment in China is governed by one of the most tightly regulated reproductive medicine frameworks globally. The National Health Commission authorizes and monitors all assisted reproductive technology centers, setting standards for laboratory quality, clinician qualifications, ethical oversight, and patient safety. Hospitals are required to maintain transparent documentation, informed consent processes, and regular quality audits, reinforcing institutional accountability.
Specialist training standards ensure fertility physicians and embryologists undergo structured education and ongoing professional development. Many participate in international research collaborations and conferences, supporting evidence-based practice and alignment with global reproductive medicine standards. Advanced medical technologies, including digital diagnostics and laboratory automation, are increasingly embedded in routine care, enhancing traceability and quality control.
China has also developed clearer governance for international patient services within public hospitals, supporting ethical medical tourism principles. Dedicated international departments commonly assist with documentation, interpreter services, and administrative coordination, helping patients navigate complex regulatory environments with clarity.
Restrictions and practical considerations:
Eligibility for certain fertility treatments may be influenced by national regulations, institutional policies, and ethical guidelines. Foreign patients may need to plan multiple visits, manage visa validity, and arrange follow-up testing or care after returning home. Understanding these practical limitations is an important part of treatment planning.
Best Clinic Abroad is a medical travel facilitator, not a medical provider, and supports patients by helping them understand the non-clinical aspects of accessing fertility care abroad. It does not provide diagnoses, treatment recommendations, or influence clinical decisions, which are made exclusively by licensed fertility specialists and accredited hospitals. Its role centers on coordination, documentation clarity, and administrative guidance.
➤ Hospital coordination - Support communication and coordination with accredited hospitals
➤ Appointment support - Assist with scheduling and organizing consultations
➤ Communication assistance - Help patients understand next steps without replacing medical advice
➤ Logistical guidance - Offer non-clinical support related to travel planning
All medical decisions remain the responsibility of licensed physicians and accredited institutions, and patients who wish to better understand administrative processes may choose to engage with Best Clinic Abroad for guidance on potential next steps.
How many IVF clinics are there in China?
China has several hundred authorized IVF and assisted reproductive technology clinics, all of which must be approved and regulated by the National Health Commission to operate legally.
Why is China's fertility so low?
China’s low fertility rate is influenced by multiple social, economic, and demographic factors, including urbanization, delayed childbearing, work-life balance challenges, and changing family preferences.
Which country is best for fertility treatment?
There is no single country that is universally best for fertility treatment. The suitability of care depends on regulatory frameworks, specialist expertise, ethical guidelines, and individual medical circumstances.
Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. It reflects non-clinical observation of healthcare coordination processes and institutional practices in China and does not represent direct medical practice. Diagnosis and treatment decisions should always be made in consultation with a licensed medical specialist based on individual clinical evaluation.
Last updated: January 2026